PASW

Ping An Biomedical Co., Ltd.
CAPPED RATING

Ping An Biomedical Co., Ltd. (PASW) is rated D+ (1.6/5) on Deltasharpe Prism, scored against Consumer Cyclical sector peers. Its strongest pillar is Value (B); its weakest is Growth (F). The rating has held at D+ for 8 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.6 / 5.0
D+
Value
B
Factor Score 3.4 / 5.0
Growth
F
Factor Score 0.1 / 5.0
Profitability
D-
Factor Score 1.0 / 5.0
Momentum
D-
Factor Score 0.9 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA -0.8
Rev Growth YoY -47.4%
Gross Margin 9.3%
Price Return 3M -71.5%
Price Return 12M -94.1%
Catalyst Signal 0.00
Market Cap $4.3M
TTM Revenue $25.5M
Price / Sales 0.2
ROE -11.4%

Historical Factor Score Progression

Held D+ for 8 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 B (3.4) F (0.1) D- (1.0) D- (0.9) C+ (2.6) D+ (1.6)
2026-11-07 B+ (3.5) F (0.1) D- (1.0) F (0.7) C+ (2.5) D+ (1.6)
2026-10-31 B (3.3) F (0.1) D- (1.0) C (2.2) C+ (2.6) D+ (1.8)
2026-10-24 B (3.2) F (0.1) D- (1.0) C (2.2) C+ (2.6) D+ (1.8)
2026-10-17 B- (3.1) F (0.1) D- (1.0) C- (1.9) C+ (2.6) D+ (1.7)
Page 1 of 4